Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer

BJU International

Volumn 113, Issue 1, 2014, Pages 43-50

  Aizer, Ayal A ^a   Chen, Ming Hui ^b   Hattangadi, Jona ^a   D'Amico, Anthony V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

active surveillance; non curative; prostate cancer; prostatectomy; radiation; undergrading

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ANTIGEN DETECTION; ARTICLE; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER THERAPY; COHORT ANALYSIS; CONTROLLED STUDY; CRYOSURGERY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; RISK FACTOR; TREATMENT INDICATION;

ACTIVE SURVEILLANCE; NON-CURATIVE; PROSTATE CANCER; PROSTATECTOMY; RADIATION; UNDERGRADING;

AGE FACTORS; AGE OF ONSET; AGED; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM GRADING; PATIENT SELECTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84890481758     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11789.x     Document Type: Article

References (33)

1. Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155: 762-771
2. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-990
3. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725-732
4. Crawford ED, Grubb R 3rd, Black A, et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol 2011; 29: 355-361
5. Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011; 29: 2185-2190
6. Ward JF, Jones JS,. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int 2012; 109: 1648-1654
7. NIH State-of-the-Science Conference. Role of Active Surveillance in the Managementof Men With Localized Prostate Cancer. 2011. Available at: http://consensus.nih.gov/2011/prostate.htm. Accessed 21 December 2011
8. Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G,. Prostate cancer in the elderly: Frequency of advanced disease at presentation and disease-specific mortality. Cancer 2012; 118: 3062-3070
9. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98: 529-534
10. Mitin T, Chen MH, Zhang Y, et al. Diabetes Mellitus, Race and the Odds of High Grade Prostate Cancer in Men Treated With Radiation Therapy. J Urol 2011; 186: 2233-2237
11. Naughton CK, Miller DC, Mager DE, Ornstein DK, Catalona WJ,. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol 2000; 164: 388-392
12. Uno H, Nakano M, Ehara H, Deguchi T,. Indications for extended 14-core transrectal ultrasound-guided prostate biopsy. Urology 2008; 71: 23-27
13. Eskicorapci SY, Baydar DE, Akbal C, et al. An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer. Eur Urol 2004; 45: 444-448; discussion 8-9
14. King CR, McNeal JE, Gill H, Presti JC Jr,. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients. Int J Radiat Oncol Biol Phys 2004; 59: 386-391
15. Moussa AS, Kattan MW, Berglund R, Yu C, Fareed K, Jones JS,. A nomogram for predicting upgrading in patients with low- and intermediate-grade prostate cancer in the era of extended prostate sampling. BJU Int 2010; 105: 352-358
16. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer 2011. Available at: http://www.nccn.org. Accessed 26 November 2011
17. Suardi N, Gallina A, Capitanio U, et al. Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients. Cancer 2012; 118: 973-980
18. Walz J, Gallina A, Saad F, et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 2007; 25: 3576-3581
19. Litton G, Kane D, Clay G, Kruger P, Belnap T, Parkinson B,. Multidisciplinary cancer care with a patient and physician satisfaction focus. J Oncol Pract 2010; 6: e35-37
20. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA 2009; 302: 1202-1209
21. Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL,. Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst 2001; 93: 1822-1823
22. Shah JB, McKiernan JM, Elkin EP, Carroll PR, Meng MV,. Prostate biopsy patterns in the CaPSURE database: evolution with time and impact on outcome after prostatectomy. J Urol 2008; 179: 136-140
23. Suardi N, Briganti A, Gallina A, et al. Testing the most stringent criteria for selection of candidates for active surveillance in patients with low-risk prostate cancer. BJU Int 2010; 105: 1548-1552
24. Kim JW, Lee HY, Hong SJ, Chung BH,. Can a 12 core prostate biopsy increase the detection rate of prostate cancer versus 6 core?: a prospective randomized study in Korea. Yonsei Med J 2004; 45: 671-675
25. de la Rosette JJ, Wink MH, Mamoulakis C, et al. Optimizing prostate cancer detection: 8 versus 12-core biopsy protocol. J Urol 2009; 182: 1329-1336
26. Nava L, Montorsi M, Consonni P, et al. Results of a prospective randomized study comparing 6, 12, 18 transrectal ultrasound guided sextant biopsies in patients with elevated PSA, normal DRE and normal prostatic ultrasound. J Urol 1997; 157 (Suppl.): 59A: 226
27. Stamatiou K, Alevizos A, Karanasiou V, et al. Impact of additional sampling in the TRUS-guided biopsy for the diagnosis of prostate cancer. Urol Int 2007; 78: 313-317
28. Babaian RJ, Toi A, Kamoi K, et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000; 163: 152-157
29. Ghani KR, Dundas D, Patel U,. Bleeding after transrectal ultrasonography-guided prostate biopsy: a study of 7-day morbidity after a six-, eight- and 12-core biopsy protocol. BJU Int 2004; 94: 1014-1020
30. Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J,. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006; 175: 1605-1612
31. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A,. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126-131
32. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203-213
33. Murphy JX, Xu J, Kochanek KD, and the Division of Vital Statistics. National Vital Statistics Reports. Deaths: Preliminary Data for 2010; 60: 4. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60-04.pdf. Accessed 30 March 2012